BioSymetrics Collaborates with Janssen and Sema4 to Predict the Onset of COVID-19

As part of the collaboration, the parties will use BioSymetrics’ Contingent-AI™ engine across several projects to characterize high-risk populations, measure and predict disease progression based on biological risk factors and treatment course, and identify markers for clinical phenotype and severity of disease.

Read More

MOA Prediction Platform to Help With COVID-19 Research

BioSymetrics Mechanism of Action Prediction Platform framework will be put to work both in prioritizing chemical libraries and in predicting mechanism for identified compounds.

Per the three COVID-19 research initiatives announced by the SCN in the post below, we will be working with William Stanford, Amy Wong, Molly Shoichet, Stephen Juvet, Samira Mubareka, Scott Gray-Own, and Mitchel Sabloff as a component of their research.

We will also have the opportunity to screen one of our own pre-clinical leads.

Please follow us on LinkedIn where were will post updates on this project as they become available.

Uniting Against COVID-19

Already working with clinicians, leveraging international collaborations to put prediction platforms in place, and re-investigating our drug lead pipeline, BioSymetrics will pursue any collaboration to have a positive impact against COVID and support the heroes working tirelessly in the hospitals and clinics around the world.

Read More